ArticleHaematologica2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
Claire Harrison, Abdulraheem Yacoub, Bart Scott, Adam Mead, Aaron T Gerds, Jean-Jacques Kiladjian, Ruben Mesa, Miklos Egyed, Christof Scheid, Valentin Garcia Gutierrez and 4 more
Open access · goldAbstract readLetter
In one paragraphArticle in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors at 12 institutions in 6 countries.
Claire HarrisonGuy's and St Thomas' NHS Foundation Trust, London. Claire.Harrison@gstt.nhs.uk.
Abdulraheem YacoubThe University of Kansas Cancer Center, Kansas City.
Bart ScottFred Hutchinson Cancer Research Center, Seattle, WA.
Adam MeadUniversity of Oxford, Oxford.
Aaron T GerdsCleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Jean-Jacques KiladjianHôpital Saint-Louis, Université Paris Cité, Paris.
Ruben MesaMays Cancer Center at UT Health San Antonio, San Antonio.
Miklos EgyedSomogy County Mór Kaposi General Hospital, Kaposvár.
Christof ScheidUniversitätsklinikum Köln (AöR), Cologne.
Valentin Garcia GutierrezHospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid.
Jennifer O'SullivanUniversity of Oxford, Oxford.
Sarah BuckleyCTI Biopharma Inc, Seattle, WA.
Kris KanellopoulosCTI Biopharma Inc, Seattle, WA.
John MascarenhasIcahn School of Medicine at Mount Sinai, New York.
CTI BioPharma (United States) · USUniversity of Oxford · GBCentrum für Integrierte Onkologie · DECleveland Clinic · USFred Hutch Cancer Center · USGuy's and St Thomas' NHS Foundation Trust · GBHôpital Saint-Louis · FRIcahn School of Medicine at Mount Sinai · USInstituto Ramón y Cajal de Investigación Sanitaria · ESSomogy Megyei Kaposi Mór Oktató Kórház · HUThe University of Kansas Cancer Center · USThe University of Texas Health Science Center at San Antonio · US
Funding
Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patientsR01CA262041 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jennifer Lynne Huberty, Ruben A. Mesa · 2022 to 2026
$2.8MCancer Research UK 26988Cancer Research UK 27125Cancer Research UK 27723NCI NIH HHS R01 CA262041
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Primary MyelofibrosisBridged-Ring CompoundsCompassionate Use TrialsHumansJanus Kinase 2Pyrimidines11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeneBridged-Ring CompoundsJanus Kinase 2Pyrimidines
Identifiers
PMID36601980
PMCPMC10316250
OpenAlexW4313545299
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390